Charles River Laboratories International, Inc. (NYSE:CRL) insider David Ross Smith sold 2,552 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the transaction, the insider now owns 11,671 shares of the company’s stock, valued at $783,124.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

David Ross Smith also recently made the following trade(s):

  • On Thursday, June 8th, David Ross Smith sold 945 shares of Charles River Laboratories International stock. The shares were sold at an average price of $95.00, for a total value of $89,775.00.

Charles River Laboratories International, Inc. (NYSE:CRL) traded up 1.12% during mid-day trading on Wednesday, hitting $99.68. The stock had a trading volume of 13,511 shares. The firm has a market cap of $4.74 billion, a P/E ratio of 26.27 and a beta of 1.02. The stock has a 50-day moving average price of $99.68 and a 200 day moving average price of $92.13. Charles River Laboratories International, Inc. has a 12-month low of $67.20 and a 12-month high of $102.32.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.20 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has initiated a share repurchase program on Wednesday, May 10th that allows the company to buyback $150.00 million in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Charles River Laboratories International, Inc. (CRL) Insider Sells 2,552 Shares of Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/insider-selling-charles-river-laboratories-international-inc-crl-insider-sells-2552-shares-of-stock/1494678.html.

Several research analysts recently weighed in on CRL shares. Jefferies Group LLC reiterated a “buy” rating and set a $106.00 price target on shares of Charles River Laboratories International in a research report on Friday, April 21st. Citigroup Inc. restated a “neutral” rating and issued a $104.00 price objective (up from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. Barclays PLC set a $90.00 price objective on Charles River Laboratories International and gave the company a “hold” rating in a research report on Saturday, May 13th. Credit Suisse Group restated a “neutral” rating and issued a $95.00 price objective (up from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $96.94.

Several institutional investors have recently modified their holdings of the company. Koch Industries Inc. acquired a new position in shares of Charles River Laboratories International during the second quarter worth about $240,000. Ameritas Investment Partners Inc. increased its position in shares of Charles River Laboratories International by 2.1% in the second quarter. Ameritas Investment Partners Inc. now owns 14,256 shares of the medical research company’s stock worth $1,442,000 after buying an additional 291 shares during the period. Castleark Management LLC acquired a new position in shares of Charles River Laboratories International during the second quarter worth about $507,000. The Manufacturers Life Insurance Company increased its position in shares of Charles River Laboratories International by 2.2% in the second quarter. The Manufacturers Life Insurance Company now owns 69,954 shares of the medical research company’s stock worth $7,076,000 after buying an additional 1,505 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Charles River Laboratories International during the second quarter worth about $344,000. 93.79% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.